PETROS PHARMACEUTICALS INC (PTPI) Fundamental Analysis & Valuation

NASDAQ:PTPI • US71678J2096

Current stock price

0.0664 USD
-0.06 (-46.45%)
At close:
0.0356 USD
-0.03 (-46.39%)
After Hours:

This PTPI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. PTPI Profitability Analysis

1.1 Basic Checks

  • PTPI had negative earnings in the past year.
  • In the past year PTPI has reported a negative cash flow from operations.
  • In the past 5 years PTPI always reported negative net income.
  • In the past 5 years PTPI always reported negative operating cash flow.
PTPI Yearly Net Income VS EBIT VS OCF VS FCFPTPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -251.96%, PTPI is doing worse than 92.39% of the companies in the same industry.
Industry RankSector Rank
ROA -251.96%
ROE N/A
ROIC N/A
ROA(3y)-118.22%
ROA(5y)-79.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTPI Yearly ROA, ROE, ROICPTPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • The Gross Margin of PTPI (76.28%) is better than 84.26% of its industry peers.
  • In the last couple of years the Gross Margin of PTPI has grown nicely.
  • PTPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.38%
GM growth 5Y7.84%
PTPI Yearly Profit, Operating, Gross MarginsPTPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. PTPI Health Analysis

2.1 Basic Checks

  • PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PTPI has more shares outstanding
  • PTPI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PTPI is higher compared to a year ago.
PTPI Yearly Shares OutstandingPTPI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
PTPI Yearly Total Debt VS Total AssetsPTPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • PTPI has an Altman-Z score of -18.76. This is a bad value and indicates that PTPI is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of PTPI (-18.76) is worse than 80.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.76
ROIC/WACCN/A
WACC6.75%
PTPI Yearly LT Debt VS Equity VS FCFPTPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • PTPI has a Current Ratio of 0.40. This is a bad value and indicates that PTPI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of PTPI (0.40) is worse than 93.91% of its industry peers.
  • PTPI has a Quick Ratio of 0.40. This is a bad value and indicates that PTPI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • PTPI has a Quick ratio of 0.33. This is amonst the worse of the industry: PTPI underperforms 93.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.33
PTPI Yearly Current Assets VS Current LiabilitesPTPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PTPI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 14.32% over the past year.
  • PTPI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -57.42%.
  • The Revenue for PTPI have been decreasing by -19.98% on average. This is quite bad
EPS 1Y (TTM)14.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320.26%
Revenue 1Y (TTM)-57.42%
Revenue growth 3Y-13.17%
Revenue growth 5Y-19.98%
Sales Q2Q%-87.54%

3.2 Future

  • PTPI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.51% yearly.
  • Based on estimates for the next years, PTPI will show a very strong growth in Revenue. The Revenue will grow by 43.00% on average per year.
EPS Next Y48.83%
EPS Next 2Y21.8%
EPS Next 3Y18.67%
EPS Next 5Y18.51%
Revenue Next Year0.76%
Revenue Next 2Y0.17%
Revenue Next 3Y26.71%
Revenue Next 5Y43%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PTPI Yearly Revenue VS EstimatesPTPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PTPI Yearly EPS VS EstimatesPTPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. PTPI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PTPI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTPI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTPI Price Earnings VS Forward Price EarningsPTPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTPI Per share dataPTPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

  • PTPI's earnings are expected to grow with 18.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.8%
EPS Next 3Y18.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PTPI Dividend Analysis

5.1 Amount

  • PTPI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

PTPI Fundamentals: All Metrics, Ratios and Statistics

PETROS PHARMACEUTICALS INC

NASDAQ:PTPI (5/21/2025, 8:00:01 PM)

After market: 0.0356 -0.03 (-46.39%)

0.0664

-0.06 (-46.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength65.22
Industry Growth16.77
Earnings (Last)11-13
Earnings (Next)N/A
Inst Owners1.13%
Inst Owner Change0%
Ins Owners1.01%
Ins Owner Change96.83%
Market Cap2.07M
Revenue(TTM)5.11M
Net Income(TTM)-26.80M
Analysts82.86
Price TargetN/A
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.63%
Min Revenue beat(2)-44.58%
Max Revenue beat(2)15.32%
Revenue beat(4)1
Avg Revenue beat(4)-8.97%
Min Revenue beat(4)-44.58%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-91.45
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.16
BVpS-0.24
TBVpS-0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -251.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.28%
FCFM N/A
ROA(3y)-118.22%
ROA(5y)-79.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.38%
GM growth 5Y7.84%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.87%
Cap/Sales 0.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.33
Altman-Z -18.76
F-Score5
WACC6.75%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320.26%
EPS Next Y48.83%
EPS Next 2Y21.8%
EPS Next 3Y18.67%
EPS Next 5Y18.51%
Revenue 1Y (TTM)-57.42%
Revenue growth 3Y-13.17%
Revenue growth 5Y-19.98%
Sales Q2Q%-87.54%
Revenue Next Year0.76%
Revenue Next 2Y0.17%
Revenue Next 3Y26.71%
Revenue Next 5Y43%
EBIT growth 1Y53.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.87%
OCF growth 3YN/A
OCF growth 5YN/A

PETROS PHARMACEUTICALS INC / PTPI Fundamental Analysis FAQ

What is the fundamental rating for PTPI stock?

ChartMill assigns a fundamental rating of 1 / 10 to PTPI.


Can you provide the valuation status for PETROS PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to PETROS PHARMACEUTICALS INC (PTPI). This can be considered as Overvalued.


What is the profitability of PTPI stock?

PETROS PHARMACEUTICALS INC (PTPI) has a profitability rating of 1 / 10.


How financially healthy is PETROS PHARMACEUTICALS INC?

The financial health rating of PETROS PHARMACEUTICALS INC (PTPI) is 0 / 10.